Overview

* KalVista fiscal Q1 net product revenue at $1.4 mln from EKTERLY sales

* Company received 460 patient start forms post-EKTERLY launch, indicating strong demand

* Cash reserves at $191 mln, providing financial runway into 2027

Outlook

* KalVista has cash runway extending into 2027

Result Drivers

* EKTERLY APPROVAL - FDA approval of EKTERLY marked a significant milestone, driving immediate commercial growth

* STRONG DEMAND - KalVista received 460 patient start forms post-launch, exceeding expectations and validating unmet need for EKTERLY

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 EPS -$1.12

Q1 Net -$60.10

Income mln

Q1 $60.44

Operatin mln

g

Expenses

Q1 -$59.01

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Kalvista Pharmaceuticals Inc ( KALV ) is $30.00, about 48.7% above its September 10 closing price of $15.39

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)